Citadel Advisors’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Citadel Advisors’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,383	Closed	-$2.93K	–	15966
2024 Q4	$2.93K	Buy	24,383 +100	+0.4%	+$13	﹤0.01%	14039
2024 Q3	$2.53K	Sell	24,283 -300	-1%	-$40	﹤0.01%	13741
2024 Q2	$2.73K	Buy	+24,583	New	+$3.36K	﹤0.01%	13659
2023 Q3	–	Sell	-21,981	Closed	-$5.06K	–	15306
2023 Q2	$5.06K	Buy	+21,981	New	+$3.83K	﹤0.01%	13535

Citadel Advisors's BLACR Position: Q1 2025 in Review

Citadel Advisors sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 24,383 shares — an estimated $2.93K sold.

Citadel Advisors first reported a position in BLACR in Q2 2023 and held it in 4 quarters. The position peaked at $5.06K in Q2 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Citadel Advisors reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 24,383 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $2.93K.
Citadel Advisors first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 4 quarters.
Citadel Advisors's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $5.06K in Q2 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.